A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis
Citations Over Time
Abstract
Abstract A specific, accurate and precise high‐performance liquid chromatographic assay was developed for the determination of riluzole, a drug used to treat patients with amyotrophic lateral sclerosis. Samples were treated by extraction with dichloromethane followed by reversed‐phase chromatography with ultraviolet detection at 260 nm. Preset validation criteria were met from 20 to 2000 ng/mL with a linear response curve. Extraction recovery of riluzole was 65–76%. The accuracy of the method was 102–103%. Intra‐ and inter‐day coefficients of variation were in the ranges 2.8–4.9% and 1.8–9.7%. A detection limit of 5 ng/mL was found. Determination of concentrations in serum and plasma resulted in similar results below 500 ng/mL. At higher values a matrix effect cannot be excluded. This presented method can be used to monitor plasma or serum levels in ALS patients treated with riluzole. Copyright © 2004 John Wiley & Sons, Ltd.
Related Papers
- → A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis(1994)2,178 cited
- → Effects of riluzole on symptom progression in amyotrophic lateral sclerosis(1997)22 cited
- → Riluzole for Amyotrophic Lateral Sclerosis Treatment(2023)4 cited
- → Effectiveness of riluzole in the treatment of amyotrophic lateral sclerosis(2021)
- → Faculty Opinions recommendation of A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.(2011)